The Danish biotech firm Genmab has lost a potential blockbuster drug. Genmab has decided to ditch the drug candidate enapotamab vedotin for treating cancer, which the firm announces in a statement.
"We are committed to developing innovative antibody products for patients with cancer, however the data from the enapotamab vedotin expansion cohorts unfortunately does not support moving this product candidate forward," states CEO Jan van de Winkel in the press announcement.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.